Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M41.6Revenue (TTM) $M0.0Net Margin (%)-94,485.2Altman Z-Score-18.1
Enterprise Value $M25.6EPS (TTM) $-1.1Operating Margin %-94,485.2Piotroski F-Score3
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)-94,485.2Higher ROA y-yN
Price/Book2.910-y EBITDA Growth Rate %-16.1Quick Ratio7.8Cash flow > EarningsY
Price/Sales--5-y EBITDA Growth Rate %14.1Current Ratio7.8Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-94.2Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-103.6Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M24.3ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with RPRX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
RPRXJohn Paulson 2014-12-31 Sold Out -0.04%$6.02 - $10.69
($8.49)
$ 1.71-80%Sold Out0
RPRXJohn Paulson 2014-09-30 Buy 0.04%$8.77 - $22.16
($14.84)
$ 1.71-88%New holding1,000,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

RPRX is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


RPRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
PODOLSKI JOSEPHPresident and CEO 2016-02-18Buy10,000$0.9380.65view
PODOLSKI JOSEPHPresident and CEO 2016-01-07Buy11,677$1.1842.37view
Anderson KatherineCFO 2014-11-12Buy3,500$9.41-82.15view
PODOLSKI JOSEPHPresident and CEO 2014-11-12Buy4,700$9.42-82.17view
Masterson Nola EDirector 2014-09-15Buy200$14.34-88.28view
PODOLSKI JOSEPHPresident and CEO 2014-08-14Buy2,100$13.91-87.92view
Anderson KatherineCFO 2014-08-14Buy2,000$13.85-87.87view
CAIN DANIEL FDirector 2013-11-12Buy500$14.97-88.78view
PODOLSKI JOSEPHPresident and CEO 2013-10-25Buy3,000$18.03-90.68view
Anderson KatherineCFO 2013-10-25Buy1,000$17.9-90.61view

Quarterly/Annual Reports about RPRX:

News about RPRX:

Articles On GuruFocus.com
Weekly CFO Buys Highlight: RPRX, ARCT, LUB, JCS, DCIN Apr 23 2012 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Nov 10 2010 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Aug 09 2010 
Repros Therapeutics Inc. Reports Operating Results (10-Q) May 10 2010 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Nov 09 2009 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Aug 17 2009 
Repros Therapeutics Inc. Reports Operating Results (10-Q) May 11 2009 
Repros Therapeutics Inc. (RPRX) CEO Joseph Podolski buys 4,000 Shares Mar 05 2009 
Weekly CEO Buys Highlight: Medtox Scientific Inc., Provident Bankshares Corp., Escalade Inc., Repros Apr 25 2008 

More From Other Websites
REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Jul 19 2016
5 Top Biotech Performers of 2016 Jul 01 2016
REPROS THERAPEUTICS INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jul 01 2016
Research Report Initiated on Select Biotechnology Equities Jun 24 2016
REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Jun 07 2016
6 Biotechs Seriously on the Move Jun 02 2016
REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jun 01 2016
Repros Provides Update on EU Submission of Enclomiphene for the Treatment of Secondary Hypogonadism... Jun 01 2016
Repros Provides Update on EU Submission of Enclomiphene for the Treatment of Secondary Hypogonadism... Jun 01 2016
REPROS THERAPEUTICS INC. Financials May 19 2016
REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... May 18 2016
Repros Reports Positive Clinical Data for Oral Proellex® in Women With Severe Menstrual Bleeding... May 18 2016
REPROS THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers May 16 2016
Repros Announces the Appointment of Mr. Patrick Fourteau as Chairman of the Board May 16 2016
Repros Announces the Appointment of Mr. Patrick Fourteau as Chairman of the Board May 16 2016
Repros (RPRX) Q1 Loss Narrower Y/Y, Pipeline in Focus May 11 2016
Repros Therapeutics Inc.® Reports First Quarter 2016 Financial Results May 10 2016
Repros Therapeutics reports 1Q loss May 10 2016
Repros Therapeutics reports 1Q loss May 10 2016
REPROS THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition,... May 10 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)